白蛋白结合型紫杉醇联合替吉奥胶囊一线治疗晚期胰腺癌的疗效及安全性分析

Efficacy and safety of albumin-bound paclitaxel combined with Tijio capsule in first-line treatment of advanced pancreatic cancer

目的观察评价白蛋白结合型紫杉醇联合替吉奥胶囊一线治疗晚期胰腺癌的临床疗效及安全性,为临床治疗该病提供参考依据。方法按照纳入排除标准选择2021年10月至2022年10月于临沂市中心医院住院的83例晚期胰腺癌患者为研究对象,将其随机分为观察组(N=41)和对照组(N=42)。对照组采用替吉奥单药治疗,观察组则在此基础上给予患者白蛋白结合型紫杉醇治疗,比较两组临床治疗效果、生存状况、毒副反应发生情况及生活质量。结果治疗后,两组均无完全缓解患者,观察组治疗有效率为58.54%,疾病控制率为78.05%,对照组治疗有效率为33.33%,疾病控制率为64.29%,差异有统计学意义(P<0.05)。观察组患者的生存期为(10.74±0.38)个月,中位生存期为(10.92±0.45)个月,对照组患者生存期为(7.42±0.15)个月,中位生存期为(7.65±0.24)个月,差异有统计学意义(P<0.05)。观察组发生白细胞减少、中性粒细胞减少及血小板减少患者多于对照组,发生呕吐和腹泻的患者少于对照组,但两组所有毒副反应发生率比较差异无统计学意义(P>0.05)。观察组患者生活质量量表(QLQ-C30)各项条目的得分高于对照组差异有统计学意义(P<0.05)。结论晚期胰腺癌患者在替吉奥的基础上应用白蛋白结合型紫杉醇一线治疗晚期的临床疗效优于单独使用替吉奥,证明其可有效提高治疗有效率和疾病控制率,改善患者的生存状态。但该治疗方法存在一定的毒副反应,临床应加强监测,预防毒副反应的发生,提高患者的生活质量。

Objective To observe and evaluate the clinical efficacy and safety of albumin-bound paclitaxel combined with Tijio capsule in the first-line treatment of advanced pancreatic cancer,and to provide a reference for the clinical treatment of this disease.Methods According to the inclusion and exclusion criteria,83 patients with advanced pancreatic cancer admitted to Linyi Central Hospital from October 2021 to October 2022 were selected as subjects,and randomly divided into an observation group(N=41)and a control group(N=42).The control group was treated with Tijio monotherapy,and the observation group was treated with albumin-binding paclitaxel on this basis.The clinical efficacy,survival status,occurrence of toxic and side effects,and quality of life of the two groups were compared.Results After treatment,there was no complete remission in both group.The effective rate was 58.54%and the disease control rate was 78.05%in the observation group,and the effective rate was 33.33%and the disease control rate was 64.29%in the control group,with statistical significance(P<0.05).The survival time of patients in the observation group was(10.74±0.38)months,the median survival time was(10.92±0.45)months,the survival time of patients in the control group was(7.42±0.15)months,the median survival time(was 7.65±0.24)months,the difference was statistically significant(P<0.05).The incidence of leukopenia,neutropenia,and thrombocytopenia in the observation group was more than that in the control group,and the incidence of vomiting and diarrhea was less than that in the control group,but there was no statistical significance in the incidence of all toxic and side effects between the two groups(P>0.05).The scores of all items of the quality of life questionnaire core 30(QLQ-C30)in the observation group were higher than those in the control group,and the difference was statistically significant(P<0.05).Conclusion The clinical efficacy of Tijio combined with albuminbound paclitaxel in the first-line treatment of advanced pancreatic cancer is better than that of Tijio alone,which proves that Tijio can effectively improve the treatment effective rate and disease control rate,and improve the survival status of patients.However,this treatment method has certain toxic and side effects.Clinical monitoring should be strengthened to prevent the occurrence of toxic and side effects and improve the quality of life of patients.